Literature DB >> 17998944

Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.

Francesco Boccardo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17998944     DOI： 10.1038/ncponc1015

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  4 in total

1.  Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

Authors:  Marco Colleoni; Anita Giobbie-Hurder; Meredith M Regan; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; István Láng; Ian Smith; Jacquie Chirgwin; Tadeusz Pienkowski; Andrew Wardley; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

2.  Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

Authors:  Henning Mouridsen; Anita Giobbie-Hurder; Aron Goldhirsch; Beat Thürlimann; Robert Paridaens; Ian Smith; Louis Mauriac; John F Forbes; Karen N Price; Meredith M Regan; Richard D Gelber; Alan S Coates
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

Review 3.  Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Authors:  Meredith M Regan; Karen N Price; Anita Giobbie-Hurder; Beat Thürlimann; Richard D Gelber
Journal:  Breast Cancer Res       Date:  2011-05-26       Impact factor: 6.466

4.  Bone health history in breast cancer patients on aromatase inhibitors.

Authors:  Marilyn L Kwan; Joan C Lo; Li Tang; Cecile A Laurent; Janise M Roh; Malini Chandra; Theresa E Hahn; Chi-Chen Hong; Lara Sucheston-Campbell; Dawn L Hershman; Charles P Quesenberry; Christine B Ambrosone; Lawrence H Kushi; Song Yao
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.